Provectus today announced that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1," at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland.
Provectus today announced its results of operations and financial condition for the third quarter ended September 30, 2015.
Provectus announced today that it will hold its 2015 third quarter business update conference call at 5 pm Eastern Standard Time on Thursday, November 5, 2015.
Provectus today reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses."
Provectus today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.
Provectus today announced that it has completed patient accrual for its phase 2 study of the cellular and immunologic changes in the skin of patients receiving PH-10, an investigational topical treatment for atopic dermatitis and psoriasis.
Provectus today announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.
Provectus today announced its results of operations and financial condition for the second quarter ended June 30, 2015.
Provectus announced today that it will hold its 2015 second quarter business update conference call at 4 pm Eastern Daylight Time on Thursday, August 6, 2015.
Provectus announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.
Provectus announced today that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.
Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").
Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).
The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.
Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.
Provectus announced that its poster presentation titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma" is on display at the 5th European Post-Chicago Melanoma / Skin Cancer Meeting in Munich, Germany.
Provectus announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver" to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at: http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085
Provectus announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
Provectus announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.
Provectus today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.